GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma.
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.
The [R]-GemOx regimen consists of: Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; Gemcitabine - an antimetabolite; Oxaliplatin - a platinum-based alkylating antineoplastic agent.GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II studyRituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
Dosing regimen Drug Dose Mode Days Rituximab 375 mg/m2 IV infusion Day 1 Gemcitabine 1000 mg/m2 IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min Day 2 Oxaliplatin 100 mg/m2 IV infusion over 2hrs Day 2
References